Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANISTOP study of stopping ranitidine in paclitaxel premedication
NL-OMON24209Recruiting
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ranitidine and paclitaxel in Nonhematologic neoplasms (2 arms), sponsored by none. Primary endpoint: Incidence of clinically relevant hypersensitivity reactions. Started Apr 2018; status: recruiting.
02
Drugs
ranitidinepaclitaxel
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON24209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24209.